ICONIC-LEAD: Icotrokinra Clears Almost Half of Psoriasis Patients in Phase 3 Trial

Nearly half of patients with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin at week 24, according to new data presented at the 2025 America Academy of Dermatology Annual Meeting.

The trial included adults and adolescents aged 12 years and older with moderate-to-severe plaque psoriasis. Of those treated with icotrokinra, 65% achieved an Investigator’s Global Assessment (IGA) score of 0/1 (clear or almost clear skin) and 50% achieved a Psoriasis Area and Severity Index (PASI) 90 response at week 16, vs. 8% and 4%, respectively, in the placebo group (P < 0.001 for both endpoints). By week 24, these figures increased to 74% for IGA 0/1 and 65% for PASI 90.

Almost half of icotrokinra-treated patients (46%) achieved completely clear skin (IGA 0), and 40% reached PASI 100 by week 24. The safety profile was favorable, with adverse events occurring in 49% of participants in both the treatment and placebo groups.

"People living with moderate-to-severe plaque psoriasis are seeking options that balance efficacy, safety and ease of use," said Robert Bissonnette, MD, Chairman at Innovaderm Research, Montreal, Canada and ICONIC-LEAD study investigator, in a press release from the manufacturer (J&J)."These study results are promising and show the potential for treatment with icotrokinra to offer patients the unique combination of complete skin clearance and a favorable safety profile in a once daily pill."